What is a stock summary page? Click here for an overview.
Business Description
Ayala Pharmaceuticals Inc
NAICS : 325412
SIC : 2833
ISIN : US0076244062
Share Class Description:
ADXS: Ordinary SharesDescription
Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.28 | |||||
| 9-Day RSI | 42.47 | |||||
| 14-Day RSI | 45.59 | |||||
| 3-1 Month Momentum % | 57.89 | |||||
| 6-1 Month Momentum % | -21.74 | |||||
| 12-1 Month Momentum % | -91.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -157588.89 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.2 | |||||
| EV-to-Forward-EBIT | -0.15 | |||||
| EV-to-EBITDA | -0.2 | |||||
| EV-to-Revenue | 539.11 | |||||
| EV-to-Forward-Revenue | 0.37 | |||||
| Earnings Yield (Greenblatt) % | -500 | |||||
| FCF Yield % | -1000.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ADXS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ayala Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.009 | ||
| EPS (TTM) ($) | -5.431 | ||
| Beta | 2.64 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.66 | ||
| Volatility % | 461.86 | ||
| 14-Day RSI | 45.59 | ||
| 14-Day ATR ($) | 0.015794 | ||
| 20-Day SMA ($) | 0.042905 | ||
| 12-1 Month Momentum % | -91.89 | ||
| 52-Week Range ($) | 0.0012 - 0.777 | ||
| Shares Outstanding (Mil) | 42.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ayala Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ayala Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ayala Pharmaceuticals Inc Frequently Asked Questions
What is Ayala Pharmaceuticals Inc(ADXS)'s stock price today?
The current price of ADXS is $0.03. The 52 week high of ADXS is $0.78 and 52 week low is $0.00.
When is next earnings date of Ayala Pharmaceuticals Inc(ADXS)?
The next earnings date of Ayala Pharmaceuticals Inc(ADXS) is 2025-05-15 Est..
Does Ayala Pharmaceuticals Inc(ADXS) pay dividends? If so, how much?
Ayala Pharmaceuticals Inc(ADXS) does not pay dividend.
Guru Commentaries on OTCPK:ADXS
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers